ETTX News and Press, Entasis Therapeutics Holdings Inc. From 11/05/20

Entasis Therapeutics (ETTX): Q3 GAAP EPS of -$0.37 beats by $0.13. Cash, cash equivalents and short-term investments of $61.2MPress Release For further details see: Entasis Therapeutics EPS beats by $0.13

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its third quarter 2020 financial results and provided a b...

SG Blocks (SGBX +100% on entering exclusive master development and production agreement with Blink Charging.Hertz Global Holdings (HTZ +49% on $1.65B DIP financing.ASLAN Pharmaceuticals (ASLN +49% on plans to develop ASLAN003 for autoimmune diseases.ReWalk Roboti...

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the ...

WALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Off...

Entasis Therapeutics (NASDAQ: ETTX )   will issue 9.3M units at $2.675/unit, in a private placement to Innoviva and another institutional investor, for gross proceeds of ~$25M. More news on: Entasis Therapeutics Holdings Inc., Healthcare stocks news, , Read more ...

WALTHAM, Mass., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today it has entered into a definitiv...

Entasis Therapeutics (NASDAQ: ETTX ) : Q2 GAAP EPS of -$0.78 misses by $0.04 . More news on: Entasis Therapeutics Holdings Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its second quarter 2020 financial results and provided a ...

WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Offi...